Results of therapy of chronic urticaria in patients with IgE-dependent and IgE-independent disease profile

The main mechanism for the occurrence of urticaria is the degranulation of mast cells. It has been proven that, regardless of the activation pathway, clinical manifestations will not differ. According to the literature, up to half of cases of chronic spontaneous urticaria are autoimmune in nature, can be combined with autoimmune thyroid disease, SLE, etc., and have a more severe course.

In therapy, antihistamines are traditionally used. However, some patients do not respond to the treatment, even with a multiple increase in doses. In the treatment of urticaria resistant to traditional antihistamines, the use of Omalizumab is recommended. The purpose of the study: to determine the profile of patients with chronic urticaria, as well as to evaluate the effectiveness of treatment with Omalizumab in patients with IgE- dependent and IgE-independent chronic urticaria.

Eight-one patients with chronic urticaria (60 adults, 21 children) were examined. Patients before the start of therapy had a long history of CU: from 1 to 20 years. Patients before the start of therapy were treated with antihistamines, but no control was obtained. An increase in the level of serum IgE was detected in 51.7% of cases in adults and 42% in children. Concomitant sensitization was determined in 48.3% of adults and 76.2% of children. In children, food, epidermal and pollen sensitization was the most common. Pollen and epidermal sensitization were more common in adults. The level of eosinophilia in the group with IgE-dependent was more pronounced than in other group (p = 0.0097). After 6 months, the group with IgE-dependent showed an improvement in the symptom score (UCT) from 3.1 CI (1.5-4.6) to 12.2 CI (10.8-13.7), (p = 0.0001). In other group, symptoms improved from 0.63 CI (0.36-1.6) to 8.1 CI (5-11.2) after 6 months (no control). After 6 months of genetically engineered biological therapy (GIBT), complete control over the symptoms of CU in group 1 was obtained in 66.7% of patients, partial — in 33.7%. In the second group, in 33.3% of cases, positive treatment results could not be achieved. Thus, genetically engineered biological therapy with Omalizumab increases the control over the course of CU. Treatment outcomes are higher in patients with an IgE-dependent disease profile.

1. Agache I., Rocha C., Pereira A., Song Y., Alonso-Coello P., Solà I., Beltran J., Posso M., Akdis C.A., et al. Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines. Allergy. 2021 Jan;76(1):59-70. doi: 10.1111/all.14547. Epub 2020 Sep 7. PMID: 32767573,

2. Bracken S.J., Abraham S. and MacLeod AS (2019) Autoimmune Theories of Chronic Spontaneous Urticaria. Front. Immunol. 10:627. Doi: 10.3389/fimmu.2019.00627.

3. Gibbs B.F., Rathling A., Zillikens D., Huber M., Haas H. Initial Fc epsilon RI-mediated signal strength plays a key role in regulating basophil signaling and deactivation. J Allergy Clin Immunol 2006;118:1060–1067. PubMed: 1708813

4. Guillen-Aguinaga S., Jauregui Presa I., Aguinaga-Ontoso E., Guillen-Grima F., Ferrer M. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis. The British journal of dermatology. 2016;175:1153-1165

5. Hasal, Eda et al. “Factors Related to Omalizumab Drug Survival and Treatment Responses in Chronic Urticaria.” International archives of allergy and immunology vol. 183,11 (2022): 1198-1208. doi:10.1159/000526148

6. Kolkhir P., Church M.K., Weller K., Metz M., Schmetzer O., Maurer M. Autoimmune chronic spontaneous urticaria: what we know and what we do not know. J Allergy Clin Immunol. 2017;139(6):1772-1781

7. Luquin E., Kaplan A.P., Ferrer M. Increased responsiveness of basophils of patients with chronic urticaria to sera but hypo-responsiveness to other stimuli. Clin Exp Allergy 2005;35:456-60.

8. Maurer M., Altrichter S., Schmetzer O., Scheffel J., Church M.K., Metz M. Immunoglobulin E-mediated autoimmunity. Fronti Immunol. 2018;9:689,

9. Nenasheva N.M., Kurbacheva O.M., Avdeev S.N., Fedosenko S.V., Emel'yanov A.V., Belevskiy A.S., Il'ina N.I., KnZyryanov S.K., et al. Practical recommendations for choosing an immunobiological preparation for the treatment of seveendotype. Russian Pulmonology. 2020; 30 (2): 227–244 (in Russian). DOI: 10.18093/0869-0189-2020-30-2-227-244)

10. Pereverzina N.O, Kruglova L.S., Musaev I.E. Present and future in the treatment of chronic spontaneous urticaria. Klinicheskaya Dermatologia I Venerologia. 2020; 19(5):604-612. (in Russian). https://doi.org/10.17116/klinderma202019051604

11. Weller K., Groffik A., Church M.K., et al. Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol 2014;133:1365-1372

12. Zhao Z.T., Ji C.M., Yu W.J., et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol 2016; 137:1742-1750